Hydrus®: The Long-Term Evidence - Summary - MDSpire
From the Journals

Hydrus®: The Long-Term Evidence

Professor Gus Gazzard* outlines the five-year results of the HORIZON study, evaluating the safety and efficacy of the Hydrus® Microstent

  • April 24, 2026

  • 5 min

Share

At the European Glaucoma Society Congress, Professor Gus Gazzard presented the five-year findings from the HORIZON study, the largest randomized controlled trial to evaluate the Hydrus Microstent in glaucoma surgery. The study, encompassing a significant follow-up rate of 80%, demonstrated that 77.2% of patients experienced at least a 20% reduction in intraocular pressure (IOP) without medication at 24 months. Additionally, the Hydrus Microstent significantly decreased postoperative IOP spikes and reduced the need for further surgeries over five years, supporting its efficacy as a treatment option.

Original Source(s)

Hydrus®: The Long-Term Evidence

  • April 24, 2026

Related Content

Focus on Focus A-Eye

The Focus A-Eye Summit in Denver, CO (May 2, 2026) will unite ophthalmology experts to advance AI applications

  • April 24, 2026

  • 1 min
Free Vision Care Clinic for Vulnerable Groups in UK

Partnership provides eye tests and glasses to people excluded from NHS services.

  • April 24, 2026

  • 2 min
Beyond IOP

Systematic review examines how lifestyle modifications could be used as complementary IOP-lowering strategies for glaucoma patients

  • April 24, 2026

  • 3 min